Modulation of P1 and EGF Expression by BaicalinReportar como inadecuado

Modulation of P1 and EGF Expression by Baicalin - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.


Heilongjiang Academy of Traditional Chinese Medicine, Harbin 150036, China


School of Food Science and Engineering, Harbin Institute of Technology, Harbin 150090, China

These authors contributed equally to this work.


Author to whom correspondence should be addressed.

Abstract Mycoplasma pneumoniae M. pneumoniae is increasingly recognized as a major cause of acute respiratory tract infections. Today, macrolides are used in the primary treatment of M. pneumoniae infection. However, with the increasing prevalence of strains resistant to macrolides, as well as reports of toxicity and adverse side effects, it is necessary to develop an alternative therapeutic agent. A compound recipe — Qinbaiqingfei pellets Qinbai — have already been approved in China as the first effective traditional Chinese medicine to be used against M. pneumoniae. Herein, we characterize the mechanism by which Qinbai interacts with M. pneumoniae and lung epithelial cells. The fact that Baicalin is the key component of Qingbai leads us to believe its study is important to elucidating the mechanism of the action of Qinbai. In this study, we describe the complex impact of Baicalin on the adhesin protein P1 of M. pneumoniae and on the expression of epidermal growth factor EGF in BALB-c mice and A549 cells infected with M. pneumonia. We draw the conclusion that Baicalin not only cured M. pneumoniae infection by inhibiting P1 expression, but also enhanced the repair of lung epithelial cells by upregulating EGF. Finally, we demonstrate that Baicalin plays a role in Qinbai treatment. View Full-Text

Keywords: M. pneumoniae; Baicalin; EGF; P1 M. pneumoniae; Baicalin; EGF; P1

Autor: Yanli Meng 1, Jinhai Huo 1,†, Weihong Lu 2,†, Xin Wang 1, Junwei Zhang 1 and Weiming Wang 1,*



Documentos relacionados